Semaglutide
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®
Novo Nordisk · Phase 3 · Status n/r · Enrollment 370
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Semaglutide injection | n/r | n/r | n/r | n/r |
| Wegovy® | n/r | n/r | n/r | n/r |
Not shown
- Semaglutide injection: endpoint not reported
- Wegovy®: endpoint not reported